Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Biotech Services HoldingsHKSE:08037 -1.54%19 PB Ratio is 3.23 as of Jul. 26, 2026, which is 1% above its 10-year median of 3.21. GuruFocus rates HKSE:08037 with a GF Score™ of 19/100 and a GF Value™ of HK$0.27 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, China Biotech Services Holdings ranks worse than 67.69% on this metric.
The historical rank and industry rank for China Biotech Services Holdings's PB Ratio or its related term are showing as below:
HKSE:08037'
s PB Ratio Range Over the Past 10 Years
Min: 0.34 Med: 3.21 Max: 6.7
Current: 3.23
During the past 13 years, China Biotech Services Holdings's highest PB Ratio was 6.70. The lowest was 0.34. And the median was 3.21.
HKSE:08037's PB Ratio is ranked worse than 67.69% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.01
vs HKSE:08037: 3.23
During the past 12 months, China Biotech Services Holdings's average Book Value Per Share Growth Rate was -27.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -31.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -11.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -2.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of China Biotech Services Holdings was 28.10% per year. The lowest was -54.80% per year. And the median was -12.60% per year.
Back to Basics: PB Ratio
China Biotech Services Holdings (HKSE:08037) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
China Biotech Services Holdings PB Ratio Related Terms
China Biotech Services Holdings PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, China Biotech Services Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Biotech Services Holdings PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, China Biotech Services Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where China Biotech Services Holdings's PB Ratio falls into.
China Biotech Services Holdings PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
China Biotech Services Holdings (HKSE:08037) has a PB Ratio of 3.23 as of Jul. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on China Biotech Services Holdings and its competitors. This is near median its historical median of 3.21. Over the past decade, China Biotech Services Holdings' PB Ratio has ranged from 0.34 to 6.70. According to the industry distribution chart, China Biotech Services Holdings ranks #132 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 67.7%.
Is China Biotech Services Holdings' PB Ratio too high?
China Biotech Services Holdings' current PB Ratio of 3.23 is near median its 10-year median of 3.21. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 6.70. The Medical Diagnostics & Research industry median PB Ratio is 2.01. China Biotech Services Holdings' value of 3.23 is 60.7% above this industry median. Based on the distribution chart, China Biotech Services Holdings ranks #132 out of 195 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, China Biotech Services Holdings has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Biotech Services Holdings' PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, China Biotech Services Holdings ranks #132 out of 195 companies for PB Ratio. This places China Biotech Services Holdings in the lower half of its industry. The industry median PB Ratio is 2.01. China Biotech Services Holdings' value of 3.23 is 60.7% above this benchmark. Historically, China Biotech Services Holdings' own PB Ratio has ranged from 0.34 to 6.70 over the past decade. While the company's 10-year median is 3.21 vs. the industry median of 2.01, China Biotech Services Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.01, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Biotech Services Holdings's current PB Ratio of 3.23 is 60.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on China Biotech Services Holdings and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Biotech Services Holdings's current PB Ratio is 3.23, which is near median its own 10-year median of 3.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Biotech Services Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Biotech Services Holdings (HKSE:08037) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.27, compared to a current price of HK$0.64 — trading 137% above its estimated fair value. The current PB Ratio is 3.23, which is near median its 10-year median of 3.21 and 60.7% above the Medical Diagnostics & Research industry median of 2.01. China Biotech Services Holdings' overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For China Biotech Services Holdings (HKSE:08037), the current PB Ratio is 3.23 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Biotech Services Holdings (HKSE:08037) Overvalued in 2026?
Based on GuruFocus' analysis, China Biotech Services Holdings stock appears to be overvalued.
The current stock price of HK$0.64 is trading 137% above its estimated GF Value™ of HK$0.27.
GuruFocus considers China Biotech Services Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:08037:
PB Ratio: 3.23 (near median its 10-year median of 3.21)
GF Value™: HK$0.27 vs. price of HK$0.64 (137% above fair value)
Industry Position: 60.7% above the Medical Diagnostics & Research median (#132 of 195)
No single metric tells the full story. See the HKSE:08037 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Biotech Services Holdings Business Description
China Biotech Services Holdings Ltd is an investment holding company. It operates through five segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Insurance brokerage, BNCT, and Others. It derives prime revenue from the Medical & health-related services segment, which involves the provision of medical laboratory testing & health check services. The group has a business presence in Hong Kong & the PRC, of which key revenue is generated from Hong Kong. Immunotherapy-provision of tumor immune cell therapy & health management services. Pharmaceutical products-sale & distribution of health-related & pharmaceutical products. Insurance brokerage services. BNCT-provision of boron neutron capture therapy treatment services, & Others-provision of logistic services.
19GF Score
Get the complete analysis for HKSE:08037
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08037 has been successfully added to your 
